MK-6837 is under clinical development by Merck and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) ...

Bempikibart (ADX-914) is under development for the treatment of atopic dermatitis and alopecia areata. It is administered through subcutaneous route and acts by targeting interleukin-7 receptor (IL-7R ...

Copper demand is expected to stay red-hot, according to Jorge Cantallopts, an executive director at the Center for Copper and ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Pharmaceutical and biotech stocks may find it tough to outperform the market in the months ahead. That is the view of UBS ...

The global semiconductor industry is making headlines, fuelled by surging demand for electronic devices and groundbreaking ...

Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF; FRA: CM5R) ("Troilus” or the "Company”), is pleased to provide a recap of its ...

Brent is also at the heart of a number of proposed changes by Transport for London (TfL), including the creation of a new ...

China Pacific Insurance’s, or CPIC's, trusted brand and extensive distribution network establish a strong foundation for steady long-term growth, thanks to continuing improvements in agent ...

The cryptocurrency space is always in the headlines, and almost always for good reasons like a heavy rate of return. Elon ...

Signals from the incoming administration indicate a possible focus on policy pivots that they believe will result in a more ...

The S&P 500's returns are measured using time-weighted returns (TWR), which don't account for cash flows like withdrawals. If you're retired and withdrawing funds, comparing your portfolio to the S&P ...